Adicet Bio Inc (ACET NASDAQ) stock market data APIs
$0.527
0.05(9.5%)
as of April 17, 2025
Adicet Bio Inc Financial Data Overview
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Prev. Close
0.527
Open
0.5776
High
0.6085
Low
0.5241
52 wk Range
0.4471-2.25
Market Cap
43 476 K
Shares Outstanding
82 686 K
EPS
-0.32
Beta
1.638
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adicet Bio Inc data using free add-ons & libraries
Get Adicet Bio Inc Fundamental Data
Adicet Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -121 147 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-17
- EPS/Forecast: -0.355
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adicet Bio Inc News
New
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif. & BOSTON, January 25, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell thera...
Adicet Bio, Inc. Announces Pricing of Public Offering
REDWOOD CITY, Calif. & BOSTON, January 23, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. ("Adicet") (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T...
Adicet Bio, Inc. Announces Proposed Public Offering
REDWOOD CITY, Calif. & BOSTON, January 22, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. ("Adicet") (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T...
Great week for Adicet Bio, Inc. (NASDAQ:ACET) institutional investors after losing 71% over the previous year
Key Insights Given the large stake in the stock by institutions, Adicet Bio's stock price might be vulnerable to their trading decisions 52% of the business is held by the top 6 shareholders Analyst ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
